Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monepantel in ALS/MND
NCT04894240Phase 1Completed
- Sponsor
- Neurizon Therapeutics
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of monepantel in amyotrophic lateral sclerosis (ALS), sponsored by Neurizon Therapeutics. Primary endpoints: Determination of Phase 2 Dose, Blood Plasma Pharmacokinetics of Monepantel at 29 days and 1 more. Started Jun 2022; status: completed.
02
Drugs
monepantel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04894240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894240.